Neurometabolic Disorders
Clinical research activity is centered on Krabbe disease, with attention to the severe neurodegenerative consequences of galactocerebrosidase deficiency and the medical needs of affected infants.
- Krabbe disease
- Infantile leukodystrophy
- Inherited metabolic disorders
The sponsor’s research interest lies in conditions involving early-onset nervous system injury and progressive loss of myelin function.
Gene Therapy
The clinical program focuses on gene transfer approaches using an AAVrh.10 vector to address the underlying enzyme defect in Krabbe disease.
- Adeno-associated viral vector
- GALC gene replacement
- Intravenous gene delivery
This area reflects a therapeutic emphasis on correcting the biological basis of lysosomal dysfunction through targeted genetic intervention.
Hematopoietic Stem Cell Transplantation
Research activity also involves children receiving hematopoietic stem cell transplantation, with interest in treatment settings where transplant care intersects with neurologic disease management.
- Stem cell transplant recipients
- Post-transplant care
- Infant treatment window
The sponsor’s clinical focus includes the period after transplant when systemic delivery of a therapeutic vector may be relevant to disease control.
Pediatric Rare Disease Therapy
The funded research is directed toward pediatric rare disease treatment, especially in very young patients with rapidly progressive neurologic decline.
- Pediatric neurology
- Rare disease medicine
- Early-life intervention
These interests place the sponsor within therapeutic development for infant-onset disorders requiring specialized clinical attention.
